| Literature DB >> 34323675 |
Lulu Yao1,2, Huimin Fu1,2, Lu Bai1,2, Wenwen Deng1,2, Fang Xie3, Ying Li3, Rong Zhang4, Xinjie Xu5, Ting Wang6, Shenghan Lai7, Jun Wang1,2.
Abstract
OBJECTIVES: Nitric oxide (NO) plays a vital role in neurological development. As an easily accessible and non-invasive fluid, saliva hasn't been evaluated for nitrite among children with autism spectrum disorder (ASD). This study aims to quantify saliva nitrite and explore its relation with serum NO.Entities:
Keywords: Autism spectrum disorder; nitrate; nitric oxide; nitrite; saliva; serum
Mesh:
Substances:
Year: 2021 PMID: 34323675 PMCID: PMC8330712 DOI: 10.1080/13510002.2021.1959133
Source DB: PubMed Journal: Redox Rep ISSN: 1351-0002 Impact factor: 4.412
Figure 1.Different pretreatment and sampling methods of saliva. (A) Scenic description of seven pretreatment methods: untreated, centrifugation, saturated ZnSO4, NaOH plus ZnSO4 and centrifugation, filtration, centrifugation plus MeOH, and NaOH plus centrifugation. (B) ratio of NO2− (t) to NO2− (t0) versus time with methods described in (A). t0 was when the first measurement was performed immediately after pre-treatment. t was when nitrite was measured at time length i: 2, 6, 12 or 24 h. (C) nitrite concentrations within 24 h with one of these two sampling methods: spitting (spit), cotton swabbing (cotton swab), followed by pretreatment of NaOH plus centrifugation.
Summary of concentrations of salivary nitrite.
| Subjects | Age (years) | No. of subjects | Analytical method | Nitrite (µM) | Ref |
|---|---|---|---|---|---|
| ASD children | 2–10 | 126 | Chemiluminescence | 4.97 ± 3.77 (0.55–16.46) | this work |
| ND children | 2–10 | 129 | Chemiluminescence | 2.66 ± 2.07 (0.23–9.83) | |
| ND individuals | – | 1 | Griess | 0–300 | [ |
| Human | – | 6 | HPLC | 65.1–193.13 | [ |
| Human | – | 4 | Ion chromatography | 802.9–1475.6 | [ |
| ND individuals | – | 4 | Capillary zone electrophoresis | 0–30 | [ |
| Adults | 20–50 | 30 | HPLC | 204–302 | [ |
| Human | – | 3 | Griess | 26–176 | [ |
| ND individuals | – | 6 | HPLC | 92.01 ± 14.11 (75.95–115.878) | [ |
| Dental patients | 60–84 | 18 | Griess | 290.78 ± 56.42 | [ |
| Adults | 19–37 | 11 | 125.86 ± 23.87 | ||
| Gingivitis | 33.9 ± 8.38 | 183 | Griess | 5.56 ± 4.53 (0.91–16.64) | [ |
| Periodontitis | 42.65 ± 8.04 | 150 | 5.55 ± 5.39 (0–18.28) | ||
| Adults | 29.9 ± 2.17 | 147 | 8.67 ± 8.68 (0.27–33.14) | ||
| Overweight or obese | 40–65 | 20 | HPLC | 62.1 ± 46.3 (13.1–180.1) | [ |
| Rampant caries | 6–12 | 30 | Griess | 32.47 ± 7.00 | [ |
| ND children | 6–12 | 30 | 75.04 ± 13.05 | ||
| Early childhood caries | <6 | 30 | Griess | 34.99 ± 5.59 | |
| ND children | <6 | 30 | 57.45 ± 11.50 | ||
| Children: DFS < 1 | 4–6 | 31 | Griess | 9.30 ± 5. 96 | [ |
Note: ND: normally developing; DFS: diseased and filled surfaces.
DFS: diseased and filled surfaces.
Figure 2.Concentrations of salivary nitrite, serum nitrite and nitrate in the ASD and Control groups. (A) salivary nitrite in the ASD and Control groups (p < 0.0001); (B) serum nitrite in the ASD and Control groups (p < 0.0001); (C) serum nitrate in the ASD and Control groups (p = 0.0109); (D) salivary nitrite of male and female participants in each group; (E) serum nitrite of male and female participants in each group; (F) serum nitrate of male and female participants in each group.
Summary of concentrations of nitrite and nitrate in blood among children.
| Subjects | Age (years) | No. of subjects | Type | Method | NO2− (µM) | NO3− (µM) | Sum (NO2− + NO3-) (µM) | Ref |
|---|---|---|---|---|---|---|---|---|
| ASD children | 2–10 | 126 | serum | Chemiluminescence | 0.26 ± 0.20 | 42.02 ± 23.97 | 42.28 ± 24.02 | this work |
| ND children | 2–10 | 129 | serum | Chemiluminescence | 0.18 ± 0.10 | 35.74 ± 13.49 | 35.92 ± 13.50 | |
| ASD children | – | 24 | plasma | Griess | N/A | N/A | 47.3 ± 5.1/10.8 | [ |
| ND children | – | N/A | N/A | 35.7 ± 4.2/11.8 | ||||
| ASD children | – | 27 | RBC | Griess | N/A | N/A | ##1.62 ± 0.49 | [ |
| ND children | – | 30 | N/A | N/A | ##0.91 ± 0.22 | |||
| ASD children | – | 26 | plasma | Griess | N/A | N/A | 37.34 ± 6.95 | [ |
| ND children | – | 22 | N/A | N/A | 27.10 ± 5.76 | |||
| ADHD | 7–11 | 30 | serum | Griess | N/A | N/A | 30.3 ± 6.7 | [ |
| ADHD + ODD | 7–11 | 15 | N/A | N/A | 36.4 ± 9.8 | |||
| ND children | 7–11 | 51 | N/A | N/A | 34.1 ± 8.6 | |||
| ND individuals | 6–15 | 13 | serum | Griess | 0.8–5.5 | 12.8–95.2 | N/A | [ |
| 16–30 | 13 | 0.8–5.0 | 0.8–76 | N/A | ||||
| 31–45 | 15 | 0.8–6.8 | 2.4–38.4 | N/A | ||||
| 45–60 | 14 | 1.0–4.9 | 0.8–42 | N/A | ||||
| > 61 | 14 | 0.8–3.9 | 0.8–38.4 | N/A |
Notes: ##: unit is µmol/g Hb;
ND: normally developing;
ADHD: attention deficit and hyperactivity disorder;
ODD: oppositional defiant disorder.
Figure 3.Correlation among saliva nitrite, serum nitrite and serum nitrate in the ASD group (A–C), in the male participants of the ASD group (D–F), and in the female participants of the ASD group (G–I).
Figure 4.Correlation among saliva nitrite, serum nitrite and serum nitrate in the Control group (A–C), in the male participants of the Control group (D–F), and in the female participants of the Control group (G–I).